Jetrea® (Ocriplasmin) - CAM 961HB
Background
FDA-Approved Indication: Jetrea (ocriplasmin) is indicated for the treatment of symptomatic vitreomacular adhesion (VMA), including when associated with a macular hole of 400 micrometers or less in diameter.
Policy
Initial Authorization Criteria
Jetrea may be considered medically necessary when all of the following criteria are met:
1. Diagnosis of vitreomacular adhesion (VMA)
2. Patient's condition is symptomatic. Symptoms may include:
- Decreased visual acuity
- Metamorphopsia (visual distortion)
- Central visual field defects
- Impaired activities of daily living attributable to vitreomacular traction
3. Patient is at least 18 years of age
4. Patient does NOT have any of the following:
- Proliferative diabetic retinopathy
- Neovascular age-related macular degeneration
- Retinal vascular occlusion
- Aphakia
- High myopia (greater than -8 diopters)
- Uncontrolled glaucoma
- Macular hole greater than 400 micrometers in diameter
- Vitreous opacification
- Lenticular or zonular instability
- History of retinal detachment in either eye
- Prior vitrectomy in the affected eye
- Prior laser coagulation of the macula in the affected eye
- Prior treatment with ocular surgery, intravitreal injection, or retinal laser photocoagulation within the previous 3 months
5. Best corrected visual acuity (BCVA) of 20/25 or worse in the eye to be treated
6. Optical coherence tomography (OCT) has been performed and confirms the diagnosis
7. Presence of vitreomacular adhesion within 6 millimeters of the macula
8. Presence of elevation of the posterior vitreous cortex consistent with vitreomacular traction
9. Prescribed by or in consultation with an ophthalmologist, preferably a retina specialist
Authorization Duration: One-time treatment authorization
References
- Inceptua. Jetrea® (ocriplasmin) Prescribing Information. Current prescribing information.
- U.S. Food and Drug Administration (FDA). Jetrea (ocriplasmin) Injection Approval Package. January 2013.
- Stalmans P, Benz MS, Gandorfer A, et al. Enzymatic Vitreolysis with Ocriplasmin for Vitreomacular Traction and Macular Holes. New England Journal of Medicine. 2012;367:606-615.
- Kaiser PK, Kampik A, Kuppermann BD, et al. Safety Profile of Ocriplasmin for Symptomatic Vitreomacular Adhesion/Vitreomacular Traction. Retina. 2015;35(6):1111-1127.
- American Academy of Ophthalmology (AAO). Preferred Practice Pattern: Idiopathic Epiretinal Membrane and Vitreomacular Traction. Current version.
- Duker JS, Kaiser PK, Binder S, et al. The International Vitreomacular Traction Study Group Classification of Vitreomacular Adhesion, Traction, and Macular Hole. Ophthalmology. 2013;120(12):2611-2619.
- National Institute for Health and Care Excellence (NICE). Ocriplasmin for Treating Vitreomacular Traction. Technology Appraisal Guidance.
Coding Section
| Code |
Number |
Description |
| CPT |
67028 |
Intravitreal injection of a pharmacologic agent [when specified as intravitreal injection of ocriplasmin, in conjunction with the HCPCS code listed below] |
| HCPCS |
J7316 |
Injection, ocriplasmin, 0.125 mg – effective on/after 01/01/2014 |
| ICD-10 |
H43.821-H43.829 |
Vitreomacular adhesion |
Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each Policy. They may not be all-inclusive.
This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology assessment program (TEC) and other non-affiliated technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.
"Current Procedural Terminology © American Medical Association. All Rights Reserved"
History From 2026 Forward
| 10/01/2026 |
New Policy |